Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs. Our mature and unique understanding of the science …

Agios is committed to creating value for shareholders by creating value for patients and healthcare providers. Find out how in our latest press releases and SEC filings, upcoming …

Agios was founded in 2008 to unlock a new field of discovery in cellular metabolism. This singular focus on metabolic disease has taken us from the development of precision therapies in …

Dec 23, 2025 · Agios Reports Third Quarter 2025 Financial Results and Provides Business Update Read More PDF Version Oct 17, 2025 Agios’ PYRUKYND® (mitapivat) Receives …

At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life …

At Agios, we are studying how PK activation could potentially benefit people with SCD. PK activation modulates 2,3-diphosphoglycerate (2,3-DPG) levels in RBCs which reduces …

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition Read More 10/30/2025 Press Release

Agios Pharmaceuticals 88 Sidney Street Cambridge, MA 02139-4169 Phone: 617-649-8600

Agios offers the myAgios ® patient support services program as a single point of engagement for eligible patients, including access support, prescription fulfillment, financial assistance, disease …

Dec 24, 2025 · Agios expects AQVESME to be available in the U.S. in late January 2026, following implementation of the AQVESME REMS program. For more information, visit …